OBJECTIVE: To compare patient retention at 3 stages of pre-antiretroviral (ART) care and 2 stages of post-ART care to identify when greatest attrition occurs. DESIGN: An observational cohort study. METHODS: We reviewed files of all adult nonpregnant individuals testing HIV-positive January 1-June 30, 2010, at a primary health clinic in Johannesburg, South Africa (N = 842). We classified retention in pre-ART stage 1 (HIV diagnosis to CD4 results notification in ≤3 months), pre-ART stage 2 (initially ineligible for ART with repeat CD4 test ≤1 year of prior CD4), pre-ART stage 3 (initiating ART ≤3 months after first eligible CD4 result), and at 0-6 and 6-12 months post-ART. RESULTS: Retention among all patients during pre-ART stage 1 was 69.8% [95% confidence interval (CI): 66.7% to 72.9%]. For patients initially ART ineligible (n = 221), 57.4% (95% CI: 49.5% to 65.0%) returned for a repeat CD4 during pre-ART stage 2. Among those who were ART eligible (n = 589), 73.5% (95% CI: 69.0% to 77.6%) were retained during pre-ART stage 3. Retention increased with time on ART, from 80.2% (95% CI: 75.3% to 84.5%) at 6 months to 95.3% (95% CI: 91.7% to 97.6%) between 6 and 12 months. Cumulative retention from diagnosis to 12 months on ART was 36.9% (95% CI: 33.0% to 41.1%) for those ART eligible and 43.0% (95% CI: 36.4% to 49.8%) from diagnosis to repeat CD4 testing within one year among those ART ineligible. CONCLUSIONS: Patient attrition in the first year after HIV diagnosis was greatest before ART initiation: more than 25% at each of 3 pre-ART stages. As countries expand HIV testing and ART programs, success will depend on linkage to care, especially before ART eligibility and initiation.
OBJECTIVE: To compare patient retention at 3 stages of pre-antiretroviral (ART) care and 2 stages of post-ART care to identify when greatest attrition occurs. DESIGN: An observational cohort study. METHODS: We reviewed files of all adult nonpregnant individuals testing HIV-positive January 1-June 30, 2010, at a primary health clinic in Johannesburg, South Africa (N = 842). We classified retention in pre-ART stage 1 (HIV diagnosis to CD4 results notification in ≤3 months), pre-ART stage 2 (initially ineligible for ART with repeat CD4 test ≤1 year of prior CD4), pre-ART stage 3 (initiating ART ≤3 months after first eligible CD4 result), and at 0-6 and 6-12 months post-ART. RESULTS: Retention among all patients during pre-ART stage 1 was 69.8% [95% confidence interval (CI): 66.7% to 72.9%]. For patients initially ART ineligible (n = 221), 57.4% (95% CI: 49.5% to 65.0%) returned for a repeat CD4 during pre-ART stage 2. Among those who were ART eligible (n = 589), 73.5% (95% CI: 69.0% to 77.6%) were retained during pre-ART stage 3. Retention increased with time on ART, from 80.2% (95% CI: 75.3% to 84.5%) at 6 months to 95.3% (95% CI: 91.7% to 97.6%) between 6 and 12 months. Cumulative retention from diagnosis to 12 months on ART was 36.9% (95% CI: 33.0% to 41.1%) for those ART eligible and 43.0% (95% CI: 36.4% to 49.8%) from diagnosis to repeat CD4 testing within one year among those ART ineligible. CONCLUSIONS:Patient attrition in the first year after HIV diagnosis was greatest before ART initiation: more than 25% at each of 3 pre-ART stages. As countries expand HIV testing and ART programs, success will depend on linkage to care, especially before ART eligibility and initiation.
Authors: Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: Bull World Health Organ Date: 2010-04-16 Impact factor: 9.408
Authors: Elena Losina; Ingrid V Bassett; Janet Giddy; Senica Chetty; Susan Regan; Rochelle P Walensky; Douglas Ross; Callie A Scott; Lauren M Uhler; Jeffrey N Katz; Helga Holst; Kenneth A Freedberg Journal: PLoS One Date: 2010-03-04 Impact factor: 3.240
Authors: Katharina Kranzer; Jennifer Zeinecker; Philip Ginsberg; Catherine Orrell; Nosindiso N Kalawe; Stephen D Lawn; Linda-Gail Bekker; Robin Wood Journal: PLoS One Date: 2010-11-02 Impact factor: 3.240
Authors: K McCarthy; M F Chersich; J Vearey; G Meyer-Rath; A Jaffer; S Simpwalo; W D F Venter Journal: Int J STD AIDS Date: 2009-12 Impact factor: 1.359
Authors: Ajay K Sethi; David D Celentano; Stephen J Gange; Richard D Moore; Joel E Gallant Journal: Clin Infect Dis Date: 2003-09-19 Impact factor: 9.079
Authors: Pamela K Kohler; Kenneth Ondenge; Lisa A Mills; John Okanda; John Kinuthia; George Olilo; Frank Odhiambo; Kayla F Laserson; Brenda Zierler; Joachim Voss; Grace John-Stewart Journal: AIDS Patient Care STDS Date: 2014-12 Impact factor: 5.078
Authors: Jennifer Velloza; Melissa H Watt; Karmel W Choi; Laurie Abler; Seth C Kalichman; Donald Skinner; Desiree Pieterse; Kathleen J Sikkema Journal: Glob Public Health Date: 2015-01-29
Authors: Gertrude Nakigozi; Fredrick E Makumbi; John B Bwanika; Lynn Atuyambe; Steven J Reynolds; Godfrey Kigozi; Fred Nalugoda; Larry W Chang; Valerian Kiggundu; David Serwadda; Maria J Wawer; Ronald H Gray; Moses R Kamya Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: Sheri A Lippman; Starley B Shade; Alison M El Ayadi; Jennifer M Gilvydis; Jessica S Grignon; Teri Liegler; Jessica Morris; Evasen Naidoo; Lisa M Prach; Adrian Puren; Scott Barnhart Journal: J Acquir Immune Defic Syndr Date: 2016-09-01 Impact factor: 3.731
Authors: Shruti H Mehta; Gregory M Lucas; Suniti Solomon; Aylur K Srikrishnan; Allison M McFall; Neeraj Dhingra; Paneerselvam Nandagopal; M Suresh Kumar; David D Celentano; Sunil S Solomon Journal: Clin Infect Dis Date: 2015-08-06 Impact factor: 9.079
Authors: Kate Clouse; Audrey Pettifor; Kate Shearer; Mhairi Maskew; Jean Bassett; Bruce Larson; Annelies Van Rie; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2013-02-03 Impact factor: 2.622